Friday, 7 November 2014

Hyderabad American Oncology Doctors’ Rare Procedure Saves a Life



Hyderabad American Oncology Doctors’ Rare Procedure Saves a Life

A nine year old boy was saved by the American Oncology doctors from Hyderabad. The boy was suffering from a very rare form cancer called Ewing’s sarcoma. The doctors have managed to install an artificial device in place of the thigh bone which was completely affected by cancer. The boy hailed from Beedar, Karnataka. When the parents were told that the boy’s condition was severe and nothing could be done, the parents visited American Oncology hospital in Hyderabad. After the tests, it was found that thigh bone of the boy had advanced stage cancer. Initially, they have done chemotherapy for the boy. However, in order to save the boy, the doctors have imported an artificial device from London.
This device was made while keeping in mind the fact that a human body grows till the age of 18. The surgical oncologist Dr. Kishore has stated that the device can be adjusted every six months based on the growth of the boy. The whole surgical process has cost approximately Rs. 16 lakh. Surgeries like this happen only around 10 to 15 times across the world in a year.
 

Monday, 3 November 2014

India might get sick before it gets rich: Krishna Kumar

India might get sick before it gets rich: Krishna Kumar
Among the earliest multinational corporations that started business in 1930, Philips India, a subsidiary of Royal Philips of the Netherlands, ruled the consumer electronics market in India for many years. But it could not hold on to its position and lost out to competition from South Korean, Japanese and Indian companies. Philips has now changed its focus and positioning. While it has stuck to its core lighting technology, healthcare now gets more importance and consumer lifestyle is a fast growing segment. In his first interview after taking over as Philips India's vice-chairman and managing director, Krishna Kumar speaks to Sounak Mitra on how the company is readying itself for the next few decades and the increasing importance of India to Philips' global operations. Edited excerpts:
After heading the healthcare division, you took over as vice-chairman and managing director of Philips India last December. Healthcare has become a major focus for Philips in India. Is it your mandate to turn healthcare into the company's largest revenue contributor?
My mandate is to build the future for Philips in India. Globally, Philips started 124 years ago with light, and light essentially took the company in two key directions. Healthcare as a division was started from imaging, which can't be done without light. In the 1980s, globally, Philips decided to have a purpose around the innovations it did. Before that we were very broad and very deep. So defining the core purpose was the key. And we decided to deliver meaningful innovations with a vision to improve the lives of 3 billion people in the world by 2025.
While we have three business verticals - healthcare, consumer lifestyle and lighting - in future, we'll have two, health technologies and lighting solutions. We are growing in all the three segments in India. Between 2008 and 2013, Philips India has been growing at 24 per cent in revenue. We are now at $1.2 billion, accounting for 3.5 per cent of Philips' global revenue. Most of the growth has come in the past five years, and we have big ambitions for the next five years.
You are ready with a five-year plan?
As a company that has been doing business in the country for the past 84 years, obviously we are planning for the next 100 years.
Which division contributes most, and which is growing fastest?
Globally, about 45 per cent of our revenue comes from healthcare, 32 per cent from lighting and 23 per cent from consumer lifestyle. In India, about 46 per cent is from lighting solutions, about 32 per cent from healthcare and the remaining 22 per cent from the consumer lifestyle business. Healthcare is a business that we started in India about 25 years ago and here we have seen the biggest swing in the past three years with a growth rate of 32 per cent in revenue. India is the first country in the world that might get sick before it gets rich, contrary to the western world, where they got rich and then they have fallen sick as they grew old. Also more than 75 per cent of the people in India have limited or no access to healthcare, both financially and geographically. So, healthcare is bound to be a focus.
How is Philips positioned in the medical devices space? Do you intend to tap healthcare services in future?
We currently play in six verticals of healthcare, radiology, cardiology, oncology, critical care, respiratory care and healthcare services. Healthcare services is a new category we started about a year ago. Until 2010, we were the No 3 player in most of the verticals and every category is full competitors with critical care the most crowded segment. We have become No 1 in all the categories except oncology. And in healthcare services, we are the only player.
We are there in more than 70 per cent of new hospitals with 150 beds. In cardiology, our market share has gone up to 63 per cent from just 36 per cent in 2010. Also, about 90 per cent of life-support ambulances are equipped with Philips devices. Mother and child care is another area which is in its infancy but growing fast. We are here for the long haul in healthcare.
Besides categories, how do you identify focus areas? What is your success mantra?
There's no magic formula. I believe in growing talent capabilities, which in turn will grow the business. This is what will boost our sustainability for the next five years, and this was what has helped us in the past five years. We see horizons of growth in the next five years.
We at Philips India will focus on existing large businesses. We will develop new markets and new categories within existing markets for sustainable growth.
We believe in building capabilities, assets and possessions (market share). Asset is what we can leverage, the brand. It's not that we are the aam admi brand. That's no more what Philips is. Our reach and network - we are the deepest penetrated player in lighting, and the second deepest in healthcare.
Capabilities for us are the talent pool and getting the future pipeline ready. India is the second biggest talent exporting nation for Philips.
How hopeful are you about lighting and consumer lifestyle?
In lighting, we play in almost every aspect, home, business, public, office, hospitality, hospitals, industries, street, sports, entertainment and retail. The opportunity is huge. About 40 per cent of India is not yet lit and India will be third largest energy consuming nation. We need to invest to save energy. Over the next few years, India will move into digital and connected lighting. We have grown at 80 per cent in professional LED lighting while the market has grown at just 40 per cent in the past few years. LED as a segment will definitely grow faster, and we have been shaping the market. But even the conventional lighting technologies will not die in India. GLS is still about 50 per cent of the total light points in India. Innovations will play a key role here. And we plan to expand our retail presence with about 1,000 light lounges in the next 3-4 years.
Consumer lifestyle is a rocking category in India. Here we focus on healthy living, healthy eating, healthy lifestyle, wellness, personal health and healthy beverages. And each one is growing fast on relatively small bases. We are driving the change in people's habits. The target group is different for each sub-category. We have clear leadership in consumer lifestyle, and we are also creating new markets in this segment. We choose to play in certain categories and we dominate.
From 12 factories, Philips had come down to two, and then added three. Also, you have expanded your research and development centre in Bangalore. Is it the local demand, or is India's importance increasing for Philips globally?
Local for local is definitely a key. With high customs duty, we need to have local development and manufacturing, especially in a price sensitive market like India. About 95 per cent of our lighting products, 60 per cent consumer lifestyle products and 10 per cent healthcare products sold in India are locally manufactured. And we do export some in all the categories.
We have 9,500 people in India. Of this, 3,000 are in research and development, which was just about 1,000 in 2009.
We are already recognised as top class in innovation, R&D and manufacturing. We do see India becoming the R&D hub for Philips globally, essentially for growth markets like Latin America, Russia, India and China that account for about 37 per cent of Philips' total revenue. Some products are already being developed at the Bangalore R&D facility exclusively for these countries and for global markets.
Exports are also growing, and India will become an export hub for Philips in the years to come. India will also be among the top five or even top three markets in revenue for Philips. But that'll take time.

Guelph-based oncologist Basrur calls it a career

Guelph-based oncologist Basrur calls it a career
Looking back now, Dr. Vasanth Basrur could probably blame it all on the leeches.
Long before he stepped foot in medical school, treated his first cancer patient or became a trailblazer in radiation oncology, the roots of Dr. Basrur's career began in earnest as a boy of eight or nine growing up in Bangalore, India.
A neighbour had a rare condition in which she produced too many red blood cells. Young Basrur was shown by a local doctor how to treat the woman using leaches. He was hooked.
"At the time, the best way to treat someone like that was to use leeches on the skin. They would suck the blood painlessly. I would sit there and remove the leeches and put them in a bucket," he said. "Blood didn't really scare me."
On Friday, Dr. Basrur retired from Grand River Hospital after practicing medicine more than half a century. Now 83, the Guelph-based oncologist took time to reflect on his long and remarkable career.
He's treated thousands of patients while pioneering new ways to fight cancer using radiation that saved countless people from painful surgeries. Many of his treatment approaches have become the standard for cancer care today.
Dr. Basrur — whose career spanned cancer centres in Toronto, Hamilton, London and Kitchener — has been around long enough that some children he treated for leukemia returned to him decades later as adults with breast cancer.
The physician, who joined the cancer centre at Grand River Hospital 10 years ago, earned his PhD in 1957 and medical degree in 1961 from the University of Toronto.
His breakthrough thesis? Testing the effects of radiation treatment on pigs, which he kept in a laboratory basement across the street from the Princess Margaret hospital.
Over the decades, Dr. Basrur witnessed incredible advances in his field. In the early years, planning a patient's treatment was a cumbersome process that took days, fine-tuning photos from X-ray machines. Today, it's something computers and software programs do in a few minutes.
Radiation equipment has also become far more powerful, accurate and effective than it used to be, he said. At his busiest, he was treating up to 900 patients a year during the 30 years he spent with Hamilton Health Sciences.
But the best colleagues he ever had were at Grand River, where the cancer centre is a close-knit group of specialists and staff who develop a special bond, he said.
"This isn't a typical workplace. It's almost like a family," said Dr. Basrur, who was one of the first radiation oncologists to work at Grand River's new cancer centre. "They were unparalleled."
Cancer touched his own life very deeply, too. His eldest daughter, Dr. Sheela Basrur, Ontario's chief medical officer who helped guide Toronto through the SARS outbreak, succumbed to a rare form of vascular cancer in 2008.
She spent her final weeks at the Kitchener cancer centre, being treated by her father's colleagues. He says he'll never forget the kindness and professionalism she was shown.
"I'm full of gratitude to the staff at Grand River. My daughter spent the last days of her life there, and the staff was unbelievable. They went out of their way," he said.
His wife, Dr. Parvathi Basrur, was a renowned professor of veterinary genetics at the University of Guelph who trained thousands of young vets over her 60-year career. She passed away following heart surgery in 2012.
The retired doctor says he plans to travel south for a while and play more golf. But as for his desire to help others, Dr. Basrur says he'll never really lose that. That why he plans to volunteer, too.
"I will miss it," he said. "I had a great passion for helping patients in times of great difficulty. It sort of grows on you."

Investors Watch List: ZIOPHARM Oncology (NASDAQ:ZIOP), Nokia Corporation (ADR) (NYSE:NOK), Addus HomeCare Corporation (NASDAQ:ADUS), Theravance (NASDAQ:THRX), Dipexium Pharmaceuticals (NASDAQ:DPRX)

Investors Watch List: ZIOPHARM Oncology (NASDAQ:ZIOP), Nokia Corporation (ADR) (NYSE:NOK), Addus HomeCare Corporation (NASDAQ:ADUS), Theravance (NASDAQ:THRX), Dipexium Pharmaceuticals (NASDAQ:DPRX)
(NASDAQ:ZIOP) announced Net loss for the third quarter of 2014 was $6.1 million, or $(0.06) per share, compared to a net loss of $16.7 million, or $(0.20) per share, for the third quarter of 2013. Included in the loss for the third quarter of 2014 was a non-cash gain of $5.8 million compared to a non-cash loss of $7.4 million for the third quarter of 2013. The non-cash gain/loss is related to the change in the fair value of the company’s outstanding liability-classified warrants. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)’s stock on 31 October traded at beginning with a price of $3.16 and when day-trade ended the stock finally increased 8.50% to end at $3.32. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)’s showed weekly performance of 2.47%.
According to reports, Chennai plant of Nokia Corporation (ADR) (NYSE:NOK) India is on the verge of shutting down, but no support from the local government has been offered so far. There was a time when J Jayalalithaa, Chief Minister of Tamil Nadu was the first person to ask NOK during 2003-04 time to set up its first plant in India on Chennai soil. Things have changed now as the current ruling party All India Anna Dravida Munnetra Kazhagam has remained silent when NOK is facing troubles to continue its operations in India. Nokia Corporation (ADR) (NYSE:NOK) on Friday closed at $8.27. Stock institutional ownership is 11.50%. Nokia Corporation (ADR) (NYSE:NOK) distance from 50-day simple moving average (SMA50) is -0.30%.
Addus Homecare Corporation (NASDAQ:ADUS) announced its earningsresults on Thursday. The company reported $0.29 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.29, AnalystRatingsNetwork.com reports. Addus HomeCare Corporation (NASDAQ:ADUS)’s shares on Friday traded in the range of 19.51 – 20.45and ended up on $19.87. Addus HomeCare Corporation (NASDAQ:ADUS) distance from 200-day simple moving average (SMA200) is -11.44%. ADUS’s sales growth for past 5 years was 6.10% and its EPS growth for past 5 years was 18.90%.
Theravance Inc. (NASDAQ:THRX) declared a quarterly dividend on Friday, October 31st, Analyst Ratings.Net reports. Investors of record on Tuesday, November 25th will be given a dividend of 0.25 per share on Tuesday, December 23rd. This represents a $1.00 dividend on an annualized basis and a yield of 6.26%. The ex-dividend date of this dividend is Friday, November 21st.Theravance Inc. (NASDAQ:THRX)’s stock on 31 October decreased -1.17% to the closing price of $16.02. Its fifty two weeks range is $15.56 – 32.8928. The total market capitalization recorded $1.843B. Theravance Inc. (NASDAQ:THRX) monthly performance is -0.93%.
Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) on Friday closed at $10.95. Stock institutional ownership is 22.40% while insider ownership includes 0.60%. Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) distance from 50-day simple moving average (SMA50) is 9.45%.

Breast cancer emerging epidemic proportions in India, say experts

Breast cancer emerging epidemic proportions in India, say experts
Anuradha, a bubbly, creative writer-journalist with a very liberal outlook, took breast cancer head-on, after she was diagnosed with the killer-disease in 1998.
In July this year, she accepted defeat and disappeared into time-wrap. But during the 16 years of her fight against the disease, Anuradha helped the medical fraternity in spreading awareness among women as also to overcome the psychological trauma of cancer affected.
Breast cancer is developing into epidemic proportions in India, and it is now the leading cause of cancer death in Indian women. Roughly 1.5 lakh new cases are being diagnosed every year and close to 70,000 women die of breast cancer, according to Globocan (WHO) Data 2012.
To raise general awareness about breast cancer, the Kochi-based Amrita Institute of Medical Sciences (AIMS) recently organised a national seminar on 'Practical issues in the management of breast cancer'.
The seminar, inaugurated by Dr. Santosh John Abraham, President of the Association of Surgeons of India, was attended by leading oncologists from across the state and some international experts.
"Public awareness, community screening for early detection are essential interventions to save a lot of lives before the disease takes epidemic proportions," said Dr. Prem Nair, Medical Director of Amrita Institute of Medical Sciences.
"The preliminary data from our own screening programme has been very encouraging," he added.
On its part, AIMS had announced free breast screening mammogram for 100 women above the age of 50. The institute has a unique breast cancer screening clinic, for early detection and treatment. Since its inception early 2014, the Clinic has screened more than 1,000 women.
"AIMS has an advanced facility to screen breast cancer – Sentinel Lymph node Biopsy, a procedure based on newer molecular classification based on Immunohistochemical markers," said Dr. K. Pavithran, head of Medical Oncology department.
"The day-care chemotherapy unit has two state-of-the-art Laminar flow systems to ensure safe mixing and dilution of chemotherapy drugs and 36 reclining chemotherapy delivery chairs to ensure comfort to the patient," Dr.Pavithran added.
The surgical oncology team at AIMS is also studying newer techniques to reduce Lymphedema, which is a common morbidity factor for Breast Cancer Surgery, said Dr. Pavithran.

Nita Ambani to join global war against cancer

Nita Ambani to join global war against cancer
Nita Ambani, Founder and Chairperson, Reliance Foundation, has been invited to join the Board of Visitors of the University of Texas MD Anderson Cancer Centre. She will be the first Indian and the second Asian to join the institution’s board.
The MD Anderson Cancer Centre is widely acclaimed as a premier cancer centre, with a commitment to rapidly translate scientific knowledge into better cancer therapies and prevention strategies, resulting in an improved quality of life for patients.
Nita Ambani was nominated by Senator Kay Bailey Hutchison. Inviting her to join the Board, Melvyn N Klein, Chairman of the MD Anderson Board, said in a statement: “By giving your time, talents and treasure, you will help advance the institution’s mission to eliminate cancer, and ultimately make a significant difference in the lives of cancer patients and their families.”
Early detection
Oncology is a thrust area at the Sir HN Reliance Foundation Hospital and Research Centre, which was rededicated to the city of Mumbai last week by Prime Minister Narendra Modi.
The latest equipment that can help early detection of cancer as well as advances in nuclear medicine help doctors to treat cancer patients quickly and with reduced pain. Both the Sir HN Reliance Foundation Hospital and Research Centre and the MD Anderson Cancer Centre will collaborate in the area of oncology and bring to India the latest research findings and discoveries to offer patients high-quality treatment.

Sixth UAE Cancer Congress inaugurated

Sixth UAE Cancer Congress inaugurated
Three-day event to discuss and debate important oncology issues The sixth edition of the three-day UAE Cancer Congress was inaugurated on Thursday.
Opening the conference, Shaikh Nahyan Bin Mubarak Al Nahyan, Minister of Culture, Youth and Community Development, announced the approval of oncology projects that included the establishment of training programmes for cancer registry in collaboration with Dr Rajendra Badwe of the Tata Memorial Cancer Centre, India and the opening of the Gulf Molecular Biology forum lead by Dr Adeel Al Choudhary from Saudi Arabia.
Both these projects wil be run and lead by the UAE Genetic Diseases Association (UAEGDA) which is one of the promoinent supporters of this Congress.
Some of the notable highlights of the three-day Congress taking place from October 30-November 1 at the Grand Hyatt, Dubai is the launch of the Mena Chapter of the International Hepato Pancreato-Biliary Association (IHPBA) - the largest multinational, multi-speciality organisation dealing with the diseases of the liver, pancreas and biliary system.
In addition to this, the Congress also awarded five research and travel grants to doctors from India, Pakistan and Egypt.
The sixth edition will also be an excellent platform for all delegates from Middle Eastern and other countries around the globe to hold multi-disciplinary discussions, debates, workshops and symposiums on oncology covering areas including lung, gynaecology, GI, head and neck, breast surgery, nursing , nutrition, imaging, HPB disorders and others.
The conference will also hold three days of special workshops for nurse in partnership with the Oncology Nursing Society.
The Congress also has the support of the Shaukat Khannum Memorial Cancer Hospital and Research Centre, Pakistan, the Tata Memorial Cancer Centre and the Indian Cooperative Oncology Network from India.